IDH1 mutations are a strong predictor of a more favorable prognosis and a highly selective molecular marker of secondary glioblastomas that complements clinical criteria for distinguishing them from primary glioblastomas.
No takes yet. Share an insight, caveat, or question.
Nobusawa et al. (2009) studied this question.